CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. SUPPLEMENTAL AGREEMENT NO. 3 TO THE AMENDED AND...License and Supply Agreement • April 18th, 2019 • Recro Pharma, Inc. • Pharmaceutical preparations
This Supplemental Agreement No. 3 to the Amended and Restated License and Supply Agreement (Generic Verapamil) (“Supplemental Agreement No. 3”) is made the 15th day of April, 2019 (the “Supplemental Agreement No. 3 Effective Date”).
